Segment Information (Segment Data) (Details) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 27, 2025	Sep. 27, 2024	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Segment Reporting Information [Line Items]
Sales			$ 24,568,000,000	$ 23,875,000,000	$ 23,890,000,000
Less:
Depreciation			(750,000,000)	(721,000,000)	(675,000,000)
Amortization of intangible assets			(1,697,000,000)	(1,631,000,000)	(1,491,000,000)
Impairment charges			(562,000,000)	(265,000,000)	(77,000,000)
Other operating segment expenses			(16,869,000,000)	(16,395,000,000)	(16,445,000,000)
Operating profit			4,690,000,000	4,863,000,000	5,202,000,000
Identifiable assets			83,464,000,000	77,542,000,000	84,488,000,000
Capital expenditures, gross			1,156,000,000	1,392,000,000	1,383,000,000
Operating segments
Segment Reporting Information [Line Items]
Sales			24,568,000,000	23,875,000,000	23,890,000,000
Less:
Depreciation			(741,000,000)	(712,000,000)	(670,000,000)
Amortization of intangible assets			(1,697,000,000)	(1,631,000,000)	(1,491,000,000)
Impairment charges			(562,000,000)	(265,000,000)	(77,000,000)
Other operating segment expenses			(16,534,000,000)	(16,078,000,000)	(16,128,000,000)
Operating profit			5,034,000,000	5,189,000,000	5,524,000,000
Other
Segment Reporting Information [Line Items]
Sales			0	0	0
Less:
Depreciation			(9,000,000)	(9,000,000)	(5,000,000)
Amortization of intangible assets			0	0	0
Impairment charges			0	0	0
Other operating segment expenses			(335,000,000)	(317,000,000)	(317,000,000)
Operating profit			(344,000,000)	(326,000,000)	(322,000,000)
Identifiable assets			8,267,000,000	5,522,000,000	8,785,000,000
Capital expenditures, gross			8,000,000	4,000,000	100,000,000
Biotechnology | Operating segments
Segment Reporting Information [Line Items]
Sales			7,293,000,000	6,759,000,000	7,172,000,000
Less:
Depreciation			(149,000,000)	(151,000,000)	(162,000,000)
Amortization of intangible assets			(902,000,000)	(863,000,000)	(864,000,000)
Impairment charges			(101,000,000)	0	(54,000,000)
Other operating segment expenses			(4,277,000,000)	(4,060,000,000)	(4,183,000,000)
Operating profit			1,864,000,000	1,685,000,000	1,909,000,000
Identifiable assets			37,337,000,000	34,605,000,000	37,421,000,000
Capital expenditures, gross			370,000,000	447,000,000	417,000,000
Life Sciences
Less:
Impairment charges	$ 0	$ 0
Life Sciences | Operating segments
Segment Reporting Information [Line Items]
Sales			7,334,000,000	7,329,000,000	7,141,000,000
Less:
Depreciation			(185,000,000)	(167,000,000)	(129,000,000)
Amortization of intangible assets			(604,000,000)	(576,000,000)	(429,000,000)
Impairment charges			(446,000,000)	(222,000,000)	0
Other operating segment expenses			(5,579,000,000)	(5,485,000,000)	(5,374,000,000)
Operating profit			520,000,000	879,000,000	1,209,000,000
Identifiable assets			23,112,000,000	23,211,000,000	23,730,000,000
Capital expenditures, gross			186,000,000	391,000,000	320,000,000
Diagnostics | Operating segments
Segment Reporting Information [Line Items]
Sales			9,941,000,000	9,787,000,000	9,577,000,000
Less:
Depreciation			(407,000,000)	(394,000,000)	(379,000,000)
Amortization of intangible assets			(191,000,000)	(192,000,000)	(198,000,000)
Impairment charges			(15,000,000)	(43,000,000)	(23,000,000)
Other operating segment expenses			(6,678,000,000)	(6,533,000,000)	(6,571,000,000)
Operating profit			2,650,000,000	2,625,000,000	2,406,000,000
Identifiable assets			14,748,000,000	14,204,000,000	14,552,000,000
Capital expenditures, gross			$ 592,000,000	$ 550,000,000	$ 546,000,000